Until further comparative studies are available, it is, however, reasonable to assume that the magnitude of benefit for MI and stroke reduction is similar in patients receiving an SGLT1/2 inhibitor or a GLP-1 RA. This evidence concerns the gene SLC5A1 and stroke disorder.